Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Pelvic Neoplasms 1Colorectal Neoplasms 1Chylous Ascites 1Abdominal Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 283Specimen Handling 278pembrolizumab 255Cyclophosphamide 234Radiotherapy 229Nivolumab 183Cisplatin 174Biopsy 165Carboplatin 155Radiosurgery 142fludarabine 130Blood Specimen Collection 130Gemcitabine 120Surveys and Questionnaires 117Paclitaxel 115venetoclax 112Standard of Care 112Dexamethasone 105Bevacizumab 96Radiation 95Rituximab 91Oxaliplatin 89Cytarabine 88Capecitabine 86Drug Therapy 85Ipilimumab 83Doxorubicin 81durvalumab 80fludarabine phosphate 73Fluorouracil 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Embolization, Therapeutic × 90 days × Clear all
NCT07612007 2026-06-01

HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization

Mayo Clinic

Phase 2 Not yet recruiting
80 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06820320 2026-03-06

Oral Iohexol in the Management of Chylous Ascites After After Retroperitoneal or Extended Lymphadenectomy

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Completed
42 enrolled
Gynecologic

Abdominal Neoplasms, Chylous Ascites, Pelvic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡